Adverse Events Associated with Anti-Fibrotic Therapies

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.

Researchers found a significant decrease in mortality or discharge to hospice with the hydrocortisone-fludrocortisone combination versus hydrocortisone alone in septic shock cases.

The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.

Genentech’s anti-amyloid crenezumab did not slow or prevent cognitive decline in people with early-onset Alzheimer’s disease.

The standard of care does not control chronic rhinosinusitis with nasal polyps for a third of patients, but approved biologics may improve quality of life (QoL).

A therapy that rapidly demonstrates improvements in clinical outcomes may have a positive impact on medication adherence.